1. Home
  2. JELD vs PMN Comparison

JELD vs PMN Comparison

Compare JELD & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$1.47

Market Cap

138.7M

ML Signal

HOLD

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$10.44

Market Cap

115.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
PMN
Founded
1960
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Forest Products
Pharmaceuticals and Biotechnology
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.7M
115.5M
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
JELD
PMN
Price
$1.47
$10.44
Analyst Decision
Hold
Strong Buy
Analyst Count
6
3
Target Price
$3.43
$42.67
AVG Volume (30 Days)
1.7M
29.6K
Earning Date
05-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,211,181,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.93
$0.29
52 Week High
$6.98
$27.40

Technical Indicators

Market Signals
Indicator
JELD
PMN
Relative Strength Index (RSI) 49.52 40.33
Support Level $1.25 $9.31
Resistance Level $2.06 $13.80
Average True Range (ATR) 0.15 0.56
MACD -0.02 0.17
Stochastic Oscillator 38.39 54.34

Price Performance

Historical Comparison
JELD
PMN

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: